CellCAN’s CEO, Dr. Denis Claude Roy, was in attendance as a speaker at the CD34+ and Other Stem Cell Promises Symposium: Key to pluripotent clinical applications in Mulhouse, France this fall. The successful meeting allowed for fruitful discussions between the international researchers on topics such as Adult and Umbilical Cord Blood Stem Cells, Blood Stem Cells Differentiation and Diseases and Regenerative Medicine.
This meeting also underlined the success of the IRHT (Institut de Recherche en Hématologie et Transplantation) that was celebrating its 30th year of existence. Dr. Philipe Hénon, who has been its Director since its creation in 1987 and who also has been on CellCAN's International Scientific Advisory Committee, will retire at the end of the year. His work has had a tremendous impact on Regenerative Medicine and Cell Therapy and the CellCAN Network wishes to congratulate him for his contribution, his success and his legacy, which will continue to live through the IRHT.
Dr. Denis Claude Roy presented his Generating anti-leukemia cells without causing GVHD: mission possible talk in a session on the clinical applications of CD34+. Dr. Roy also seized the occasion to showcase the knowledge mobilization work of CellCAN and the benefits of this approach in the Canadian context.